RBC Capital raised the firm’s price target on Boston Scientific (BSX) to $125 from $120 and keeps an Outperform rating on the shares. Boston Scientific reported “impressive” Q2 results and raised its 2025 revenue growth and operating margin guidance, the analyst tells investors in a research note. RBC sees Boston Scientific as among the highest performing MedTech large-caps.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BSX:
- Boston Scientific price target raised to $118 from $110 at Oppenheimer
- Boston Scientific price target raised to $125 from $120 at Truist
- Boston Scientific price target raised to $123 from $117 at Baird
- Boston Scientific price target raised to $135 from $130 at UBS
- Boston Scientific price target raised to $124 from $118 at Wells Fargo